Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Acquired by Intech Investment Management LLC

Intech Investment Management LLC boosted its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 60.4% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 47,401 shares of the company's stock after purchasing an additional 17,858 shares during the quarter. Intech Investment Management LLC's holdings in Denali Therapeutics were worth $966,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Victory Capital Management Inc. raised its stake in Denali Therapeutics by 163.7% during the 3rd quarter. Victory Capital Management Inc. now owns 39,900 shares of the company's stock worth $1,162,000 after acquiring an additional 24,767 shares in the last quarter. FMR LLC boosted its position in shares of Denali Therapeutics by 3,234.3% in the 3rd quarter. FMR LLC now owns 7,831,378 shares of the company's stock valued at $228,128,000 after purchasing an additional 7,596,508 shares during the period. Algert Global LLC grew its stake in Denali Therapeutics by 82.4% during the 3rd quarter. Algert Global LLC now owns 48,630 shares of the company's stock worth $1,417,000 after buying an additional 21,975 shares during the last quarter. Proficio Capital Partners LLC acquired a new position in Denali Therapeutics during the fourth quarter worth approximately $514,000. Finally, JPMorgan Chase & Co. lifted its stake in Denali Therapeutics by 6.5% in the third quarter. JPMorgan Chase & Co. now owns 235,386 shares of the company's stock valued at $6,857,000 after buying an additional 14,324 shares during the last quarter. Institutional investors and hedge funds own 92.92% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on DNLI shares. Morgan Stanley initiated coverage on shares of Denali Therapeutics in a research report on Friday, March 7th. They set an "overweight" rating and a $33.00 target price on the stock. Deutsche Bank Aktiengesellschaft initiated coverage on Denali Therapeutics in a research report on Tuesday, February 11th. They set a "buy" rating and a $31.00 price objective for the company. Bank of America dropped their target price on Denali Therapeutics from $30.00 to $28.00 and set a "buy" rating on the stock in a report on Monday, March 10th. JPMorgan Chase & Co. lowered their price objective on shares of Denali Therapeutics from $28.00 to $24.00 and set an "overweight" rating on the stock in a research report on Tuesday, January 7th. Finally, William Blair restated an "outperform" rating on shares of Denali Therapeutics in a research report on Friday, February 28th. Two investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $37.20.

Insider Transactions at Denali Therapeutics

In other Denali Therapeutics news, CEO Ryan J. Watts sold 29,266 shares of the firm's stock in a transaction on Monday, January 6th. The stock was sold at an average price of $20.22, for a total transaction of $591,758.52. Following the completion of the transaction, the chief executive officer now owns 260,721 shares of the company's stock, valued at approximately $5,271,778.62. This trade represents a 10.09 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Carole Ho sold 12,255 shares of the company's stock in a transaction on Monday, January 6th. The shares were sold at an average price of $20.22, for a total value of $247,796.10. Following the completion of the sale, the insider now owns 178,580 shares in the company, valued at $3,610,887.60. This represents a 6.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 47,940 shares of company stock valued at $973,442 in the last ninety days. Corporate insiders own 7.90% of the company's stock.

Denali Therapeutics Price Performance

DNLI traded down $0.31 during trading on Wednesday, reaching $13.81. 796,142 shares of the stock were exchanged, compared to its average volume of 996,966. The company has a market capitalization of $2.01 billion, a price-to-earnings ratio of -5.00 and a beta of 1.46. Denali Therapeutics Inc. has a 1 year low of $13.68 and a 1 year high of $33.33. The business's 50 day moving average price is $19.50 and its two-hundred day moving average price is $23.46.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.67) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.08. On average, analysts anticipate that Denali Therapeutics Inc. will post -2.71 EPS for the current year.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.